Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 18,626 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Adult Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Safety Study of MVA Smallpox Vaccine in Subjects With a History of Atopic Dermatitis (AD)

NCT00389103
View directory record Official record
Conditions
Smallpox, Atopic Dermatitis
Interventions
MVA (smallpox vaccine)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Albuquerque, New Mexico • Portland, Oregon • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Results available

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A/H5N1in Adult - Aventis

NCT00115986
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H5N1 Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
452 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
3
States / cities
Torrance, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 21, 2026, 2:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

NCT03334786
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Fasciculation
Interventions
FLX-787-ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 21, 2026, 2:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Environmental Risk Factors for the Anti-synthetase Syndrome

NCT01276470
View directory record Official record
Conditions
Myositis, Dermatomyositis, Polymyositis, Juvenile Dermatomyositis, Juvenile Polymyositis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
2 Years to 100 Years
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
8
States / cities
Miami, Florida • Baltimore, Maryland • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

NCT06144840
View directory record Official record
Conditions
Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Interventions
Dersimelagon, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Huntington Beach, California • San Francisco, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 3 Interventional Results available

Randomized Trial in Adult Participants With Acute Migraines

NCT04571060
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
94
States / cities
Huntsville, Alabama • Mobile, Alabama • Chandler, Arizona + 86 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional

Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors

NCT00070096
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
ixabepilone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
16 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 21, 2026, 2:51 PM EDT
Not listed No phase listed Observational

Outcome Measures Study on an Adult Myoelectric Elbow-Wrist-Hand Orthosis

NCT04900896
View directory record Official record
Conditions
Stroke, Brachial Plexus Injury, Spinal Cord Injuries, Neurological Disease
Interventions
Myoelectric Elbow-Wrist-Hand Orthosis
Device
Lead sponsor
Myomo
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Chardon, Ohio • Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Not applicable Interventional Results available

A Novel Cognitive Reappraisal Intervention for Suicide Prevention

NCT03026127
View directory record Official record
Conditions
Suicide Prevention
Interventions
Cognitive Reappraisal Intervention for Suicide Prevention, Supportive Therapy
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
50 Years to 90 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Terminated Phase 4 Interventional Results available

Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

NCT04506086
View directory record Official record
Conditions
B-precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Current Wearable Heatlth Monitoring System (CWHMS)
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

NCT03275389
View directory record Official record
Conditions
Influenza, Human
Interventions
D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 39 Years
Enrollment
470 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
5
States / cities
South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults

NCT01624168
View directory record Official record
Conditions
Anxiety
Interventions
Anxiety Management Education, 10 week tai chi intervention, Enhanced tai chi instruction
Behavioral
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 40 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boone, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 21, 2026, 2:51 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Pilot Trial of DASH Feeding in Older Low Socioeconomic Adults Without Heart Failure

NCT04113291
View directory record Official record
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
DASH Diet, Usual diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants

NCT05630274
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib, Moxifloxacin, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Completed No phase listed Observational Results available

Comparison of Early and Late Therapy for Adults With Non-Operatively Treated Proximal Humerus Fractures

NCT00438633
View directory record Official record
Conditions
Proximal Humeral Fractures
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

NCT03055338
View directory record Official record
Conditions
Schizophrenia, Acute Episode
Interventions
Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 3 Interventional

8-week Pilot Study of Relaxation for Weight Loss in Adults With Chronic Kidney Disease

NCT00944138
View directory record Official record
Conditions
Obesity
Interventions
Relaxation methods
Behavioral
Lead sponsor
Edward Hines Jr. VA Hospital
Federal
Eligibility
18 Years to 88 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2010 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958
View directory record Official record
Conditions
Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions
Radezolid, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Oct 21, 2026, 2:51 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Peresolimab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Active, not recruiting Not applicable Interventional

Diet and Health in Adults With Metabolic Syndrome

NCT03935048
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Higher protein, low glycemic load diet
Dietary Supplement
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont)

NCT00920543
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 21, 2026, 2:51 PM EDT
Completed Phase 1 Interventional

Flavopiridol and Docetaxel in Treating Patients With Advanced Solid Tumors

NCT00016185
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
alvocidib, docetaxel
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2013 · Synced Oct 21, 2026, 2:51 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy

NCT06068608
View directory record Official record
Conditions
Varicella
Interventions
TNM005, Placebo, VariZIG
Drug
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 21, 2026, 2:51 PM EDT